Product Information
PREGABALIN 225 MG CAPSULE is a generic product labeled by Aurobindo Pharma Limited, priced at $0.0635 per EA under NDC 65862076490. Its NADAC has been published 138 times since Feb 14, 2024.
FDA first approved this application on Mar 29, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
225 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862076490
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PREGABALINApproval Type
Generic (ANDA)
FDA Application
ANDA205321FDA Approved
3/29/2023
TE Code
AB
On Market Since
3/29/2023
Price Statistics
The NADAC for PREGABALIN 225 MG CAPSULE has been published 138 times since Feb 14, 2024, and over the history we have for it it has declined 22.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0635 per EA |
|---|---|
| All-time high | $0.0857 (Mar 13, 2024) |
| All-time low | $0.0529 (Nov 20, 2024) |
| 52-week high | $0.0690 |
| 52-week low | $0.0543 |
| Median price | $0.0644 |
| Average price | $0.0651 |
| Largest weekly change | -29.0% (Nov 20, 2024) |
| Weeks tracked | 138 |
| Tracking since | Feb 14, 2024 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pregabalin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PREGABALIN 225 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PREGABALIN 225 MG CAPSULE, manufactured by Aurobindo Pharma Limited, is $0.0635 per EA (NDC 65862076490), effective Sep 30, 2026.
How has the price of PREGABALIN 225 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PREGABALIN 225 MG CAPSULE has declined 22.8%. It has been tracked across 138 weekly CMS publications since Feb 14, 2024.
What are the highest and lowest recorded NADAC prices for PREGABALIN 225 MG CAPSULE?
Since Feb 14, 2024, the NADAC for PREGABALIN 225 MG CAPSULE has ranged from a low of $0.0529 (Nov 20, 2024) to a high of $0.0857 (Mar 13, 2024), with a median of $0.0644 per EA.
Are there cheaper alternatives to PREGABALIN 225 MG CAPSULE?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PREGABALIN 225 MG CAPSULE, is $0.0609 per EA — about 4% below PREGABALIN 225 MG CAPSULE.
Who manufactures PREGABALIN 225 MG CAPSULE?
PREGABALIN 225 MG CAPSULE (NDC 65862076490) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.